These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 9185829)

  • 21. Flupirtine and retigabine prevent L-glutamate toxicity in rat pheochromocytoma PC 12 cells.
    Seyfried J; Evert BO; Rundfeldt C; Schulz JB; Kovar KA; Klockgether T; Wüllner U
    Eur J Pharmacol; 2000 Jul; 400(2-3):155-66. PubMed ID: 10988329
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The monoamine reuptake inhibitor BTS 74 398 fails to evoke established dyskinesia but does not synergise with levodopa in MPTP-treated primates.
    Hansard MJ; Smith LA; Jackson MJ; Cheetham SC; Jenner P
    Mov Disord; 2004 Jan; 19(1):15-21. PubMed ID: 14743355
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The behavioural effects of pramipexole, a novel dopamine receptor agonist.
    Maj J; Rogóz Z; Skuza G; Kołodziejczyk K
    Eur J Pharmacol; 1997 Apr; 324(1):31-7. PubMed ID: 9137910
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A new ethyladenine antagonist of adenosine A(2A) receptors: behavioral and biochemical characterization as an antiparkinsonian drug.
    Pinna A; Tronci E; Schintu N; Simola N; Volpini R; Pontis S; Cristalli G; Morelli M
    Neuropharmacology; 2010 Mar; 58(3):613-23. PubMed ID: 19951715
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dopamine-sensitive alternation and collateral behaviour in a Y-maze: effects of d-amphetamine and haloperidol.
    Oades R; Taghzouti K; Simon H; Le Moal M
    Psychopharmacology (Berl); 1985; 85(1):123-8. PubMed ID: 3920694
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The atypical neuroleptic profile of the glycine/N-methyl-D-aspartate receptor antagonist, L-701,324, in rodents.
    Bristow LJ; Flatman KL; Hutson PH; Kulagowski JJ; Leeson PD; Young L; Tricklebank MD
    J Pharmacol Exp Ther; 1996 May; 277(2):578-85. PubMed ID: 8627534
    [TBL] [Abstract][Full Text] [Related]  

  • 27. FK506 as effective adjunct to L-dopa in reserpine-induced catalepsy in rats.
    Singh A; Naidu PS; Kulkarni SK
    Indian J Exp Biol; 2003 Nov; 41(11):1264-8. PubMed ID: 15332494
    [TBL] [Abstract][Full Text] [Related]  

  • 28. β-asarone and levodopa coadministration increases striatal levels of dopamine and levodopa and improves behavioral competence in Parkinson's rat by enhancing dopa decarboxylase activity.
    Huang L; Deng M; Zhang S; Lu S; Gui X; Fang Y
    Biomed Pharmacother; 2017 Oct; 94():666-678. PubMed ID: 28787702
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combination therapy with flupirtine and opioid: studies in rat pain models.
    Goodchild CS; Kolosov A; Tucker AP; Cooke I
    Pain Med; 2008 Oct; 9(7):928-38. PubMed ID: 18950446
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Striatal inhibition of calpains prevents levodopa-induced neurochemical changes and abnormal involuntary movements in the hemiparkinsonian rat model.
    Chagniel L; Robitaille C; Lebel M; Cyr M
    Neurobiol Dis; 2012 Jan; 45(1):645-55. PubMed ID: 22037042
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 3,4-Methylenedioxymethamphetamine counteracts akinesia enantioselectively in rat rotational behavior and catalepsy.
    Lebsanft HB; Kohles T; Kovar KA; Schmidt WJ
    Synapse; 2005 Mar; 55(3):148-55. PubMed ID: 15602749
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Animal models of Parkinson׳s disease: Effects of two adenosine A2A receptor antagonists ST4206 and ST3932, metabolites of 2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine (ST1535).
    Stasi MA; Minetti P; Lombardo K; Riccioni T; Caprioli A; Vertechy M; Di Serio S; Pace S; Borsini F
    Eur J Pharmacol; 2015 Aug; 761():353-61. PubMed ID: 25936513
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The neurobehavioral changes induced by bilateral rotenone lesion in medial forebrain bundle of rats are reversed by L-DOPA.
    Alam M; Mayerhofer A; Schmidt WJ
    Behav Brain Res; 2004 May; 151(1-2):117-24. PubMed ID: 15084427
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antiparkinsonian effects of remacemide hydrochloride, a glutamate antagonist, in rodent and primate models of Parkinson's disease.
    Greenamyre JT; Eller RV; Zhang Z; Ovadia A; Kurlan R; Gash DM
    Ann Neurol; 1994 Jun; 35(6):655-61. PubMed ID: 8210221
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reduction of L-DOPA-induced dyskinesia by the selective metabotropic glutamate receptor 5 antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease.
    Johnston TH; Fox SH; McIldowie MJ; Piggott MJ; Brotchie JM
    J Pharmacol Exp Ther; 2010 Jun; 333(3):865-73. PubMed ID: 20231306
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Roles of Ca(2+)/calmodulin-dependent protein kinase II in subcellular expression of striatal N-methyl-D-aspartate receptors in l-3, 4-dihydroxyphenylalanine-induced dyskinetic rats.
    Gan J; Qi C; Liu Z
    Drug Des Devel Ther; 2015; 9():2119-28. PubMed ID: 25926720
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Attenuation of methamphetamine induced dopaminergic neurotoxicity by flupirtine: microdialysis study on dopamine release and free radical generation.
    Gassen M; Lamensdorf I; Armony T; Finberg JP; Youdim MB
    J Neural Transm (Vienna); 2003 Feb; 110(2):171-82. PubMed ID: 12589576
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antiparkinsonian activity of talipexole in MPTP-treated monkeys: in combination with L-dopa and as chronic treatment.
    Irifune M; Nomoto M; Fukuda T
    Eur J Pharmacol; 1994 Oct; 264(2):117-23. PubMed ID: 7851473
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of CB1 cannabinoid receptor modulating compounds on the hyperkinesia induced by high-dose levodopa in the reserpine-treated rat model of Parkinson's disease.
    Segovia G; Mora F; Crossman AR; Brotchie JM
    Mov Disord; 2003 Feb; 18(2):138-49. PubMed ID: 12539206
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Synergy between L-DOPA and a novel positive allosteric modulator of metabotropic glutamate receptor 4: implications for Parkinson's disease treatment and dyskinesia.
    Bennouar KE; Uberti MA; Melon C; Bacolod MD; Jimenez HN; Cajina M; Kerkerian-Le Goff L; Doller D; Gubellini P
    Neuropharmacology; 2013 Mar; 66():158-69. PubMed ID: 22491024
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.